[1] Buzzetti R, Zampetti S, Maddaloni E. Adult-onset autoimmune diabetes: current knowledge and implications for management. Nat Rev Endocrinol. 2017 Nov;13(11):674-686. doi: 10.1038/nrendo.2017.99.
[2] Sørgjerd EP. Type 1 Diabetes-related Autoantibodies in Different Forms of Diabetes. Curr Diabetes Rev. 2019;15(3):199-204. doi: 10.2174/1573399814666180730105351.
[3] Kumar A, de Leiva A. Latent autoimmune diabetes in adults (LADA) in Asian and European populations. Diabetes Metab Res Rev. 2017 Jul;33(5). doi: 10.1002/dmrr.2890.
[4] Fourlanos S, Dotta F, Greenbaum CJ, Palmer JP, Rolandsson O, Colman PG, Harrison LC. Latent autoimmune diabetes in adults (LADA) should be less latent. Diabetologia. 2005 Nov;48(11):2206-12.
[5] Laugesen E, Østergaard JA, Leslie RD; Danish Diabetes Academy Workshop and Workshop Speakers. Latent autoimmune diabetes of the adult: current knowledge and uncertainty. Diabet Med. 2015 Jul;32(7):843-52. doi: 10.1111/dme.12700.
[6] Carlsson S. Etiology and Pathogenesis of Latent Autoimmune Diabetes in Adults (LADA) Compared to Type 2 Diabetes. Front Physiol. 2019 Mar 26;10:320. doi: 10.3389/fphys.2019.00320.
[7] Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640-1645. doi: 10.1161/CIRCULATIONAHA.109.192644
[8] Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013; 3: 1–150
[9] Yang, L., Liu, X., Liang, H. et al. Pathophysiological characteristics in patients with latent autoimmune diabetes in adults using clamp tests: evidence of a continuous disease spectrum of diabetes. Acta Diabetol 56, 1217–1224 (2019). https://doi.org/10.1007/s00592-019-01387-6
[10] Stene LC, Barriga K, Hoffman M et al. Normal but increasing hemoglobin A1c levels predict progression from islet autoimmunity to overt type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY). Pediatr Diabetes 2006; 7(5):247–53.
[11] Tanaka, S., Ohmori, M., Awata, T. et al. Diagnostic criteria for slowly progressive insulin-dependent (type 1) diabetes mellitus (SPIDDM) (2012): report by the Committee on Slowly Progressive Insulin-Dependent (Type 1) Diabetes Mellitus of the Japan Diabetes Society. Diabetol Int 6, 1–7 (2015). https://doi.org/10.1007/s13340-014-0199-2
[12] Classification of diabetes mellitus. Geneva: World Health Organization; 2019. Licence: CC BY-NC-SA 3.0 IGO.
[13] Arranz Martín A, Lecumberri Pascual E, Brito Sanfiel MÁ, et al. Clinical and metabolic profile of patients with latent autoimmune diabetes in adults in specialized care in Madrid. Endocrinol Diabetes Nutr. 2017;64(1):34‐39. doi:10.1016/j.endinu.2016.09.001
[14] Pipi E, Marketou M, Tsirogianni A. Distinct clinical and laboratory characteristics of latent autoimmune diabetes in adults in relation to type 1 and type 2 diabetes mellitus. World J Diabetes. 2014;5(4):505‐510. doi:10.4239/wjd.v5.i4.505
[15] Zaharia OP, Bobrov P, Strassburger K, et al. Metabolic Characteristics of Recently Diagnosed Adult-Onset Autoimmune Diabetes Mellitus. J Clin Endocrinol Metab. 2018;103(2):429‐437. doi:10.1210/jc.2017-01706
[16] Nishimura A, Matsumura K, Kikuno S, Nagasawa K, Okubo M, Mori Y, Kobayashi T. Slowly Progressive Type 1 Diabetes Mellitus: Current Knowledge And Future Perspectives. Diabetes Metab Syndr Obes. 2019 Nov 28;12:2461-2477. doi: 10.2147/DMSO.S191007.
[17] Zampetti S, Capizzi M, Spoletini M, Campagna G, Leto G, Cipolloni L, Tiberti C, Bosi E, Falorni A, Buzzetti R; NIRAD Study Group. GADA titer-related risk for organ-specific autoimmunity in LADA subjects subdivided according to gender (NIRAD study 6). J Clin Endocrinol Metab. 2012 Oct;97(10):3759-65. doi: 10.1210/jc.2012-2037.
[18] Tanaka S, Okubo M, Nagasawa K, Takizawa S, Ichijo M, Ichijo S, Kaneshige M, Aida K, Shimura H, Mori Y, Kobayashi T. Predictive value of titer of GAD antibodies for further progression of beta cell dysfunction in slowly progressive insulin-dependent (type 1) diabetes (SPIDDM). Diabetol Int. 2015 May 31;7(1):42-52. doi: 10.1007/s13340-015-0211-5.
[19] Mishra R, Chesi A, Cousminer DL, et al. Relative contribution of type 1 and type 2 diabetes loci to the genetic etiology of adult-onset, non-insulin-requiring autoimmune diabetes. BMC Med. 2017;15(1):88. Published 2017 Apr 25. doi:10.1186/s12916-017-0846-0
[20] Hjort R, Löfvenborg JE, Ahlqvist E, et al. Interaction Between Overweight and Genotypes of HLA, TCF7L2, and FTO in Relation to the Risk of Latent Autoimmune Diabetes in Adults and Type 2 Diabetes. J Clin Endocrinol Metab. 2019;104(10):4815‐4826. doi:10.1210/jc.2019-00183
[21] Shahramian I, Bazi A, Sargazi A. An Overview of Celiac Disease in Childhood Type 1 Diabetes. Int J Endocrinol Metab. 2018;16(3):e66801. Published 2018 Jun 27. doi:10.5812/ijem.66801
[22] Luk AOY, Lau ESH, Lim C, et al. Diabetes-Related Complications and Mortality in Patients With Young-Onset Latent Autoimmune Diabetes: A 14-Year Analysis of the Prospective Hong Kong Diabetes Register. Diabetes Care. 2019;42(6):1042‐1050. doi:10.2337/dc18-1796
[23] Maddaloni E, Coleman RL, Agbaje O, Buzzetti R, Holman RR. Time-varying risk of microvascular complications in latent autoimmune diabetes of adulthood compared with type 2 diabetes in adults: a post-hoc analysis of the UK Prospective Diabetes Study 30-year follow-up data (UKPDS 86). Lancet Diabetes Endocrinol. 2020 Mar;8(3):206-215. doi: 10.1016/S2213-8587(20)30003-6.
[24] Wod M, Thomsen RW, Pedersen L, Yderstraede KB, Beck-Nielsen H, Højlund K. Lower mortality and cardiovascular event rates in patients with Latent Autoimmune Diabetes In Adults (LADA) as compared with type 2 diabetes and insulin deficient diabetes: A cohort study of 4368 patients. Diabetes Res Clin Pract. 2018;139:107‐113. Doi :10.1016/j.diabres.2018.02.042
[25] Ilanne-Parikka P, Eriksson JG, Lindström J, Hämäläinen H, Keinänen-Kiukaanniemi S, Laakso M, Louheranta A, Mannelin M, Rastas M, Salminen V, Aunola S, Sundvall J, Valle T, Lahtela J, Uusitupa M, Tuomilehto J; Finnish Diabetes Prevention Study Group. Prevalence of the metabolic syndrome and its components: findings from a Finnish general population sample and the Diabetes Prevention Study cohort. Diabetes Care. 2004 Sep;27(9):2135-40. doi: 10.2337/diacare.27.9.2135.